Appendix C

Biographical Sketches of Workshop Planning Committee Members and Speakers

PLANNING COMMITTEE¹

Sara Rosenbaum, J.D. (Chair), is the Harold and Jane Hirsh Professor of Health Law and Policy and Founding Chair of the Department of Health Policy at the Milken Institute School of Public Health, George Washington University. She also holds professorships in the Trachtenberg School of Public Policy and Public Administration and the Schools of Law and Medicine and Health Sciences. A graduate of Wesleyan University and Boston University Law School, Professor Rosenbaum has devoted her career to issues of health justice for populations who are medically underserved as a result of race, poverty, disability, or cultural exclusion. An honored teacher and scholar, a highly popular speaker, and a widely read writer on many aspects of health law and policy, Professor Rosenbaum has emphasized public engagement as a core element of her professional life, providing public service to 6 presidential administrations and 19 Congresses. She is best known for her work on national health reform, Medicaid and private insurance, Medicaid managed care, health care access for medically underserved communities and populations, and civil rights and health care. Professor Rosenbaum’s current research focuses on the transformation of Medicaid and its effects on poor populations and communities. Her research also focuses on national health reform, Medicaid managed

___________________

¹ Planning committee members marked with an asterisk also served as speakers or moderators at the workshop.

care, and the nation’s community health centers, the largest primary health care system for medically underserved rural and urban populations.

Frederick Appelbaum, M.D.,* is executive senior vice president and deputy director, Fred Hutchinson Cancer Research Center (Fred Hutch), and Professor, Division of Medical Oncology, University of Washington in Seattle, Washington. Dr. Appelbaum studies the biology and treatment of leukemias, lymphomas, and other blood cancers and sees patients with these disorders. He has been involved in laboratory and clinical research involving hematological malignancies for more than 4 decades. He described the first use of autologous transplantation as curative therapy for malignant lymphoma, a therapy now used to treat tens of thousands of patients annually, and he helped develop the first antibody-drug conjugate ever approved by the U.S. Food and Drug Administration. Dr. Appelbaum has received continuous peer-reviewed support from the National Institutes of Health (NIH) for 40 years and is the author or coauthor of more than 800 peer-reviewed articles. In addition to caring for patients and conducting clinical trials, he leads strategic research partnerships with the NIH and other federal agencies and helps to ensure that Fred Hutch advances are shared with the wider community. Dr. Appelbaum has made numerous landmark contributions to his field. Notably, he helped develop Fred Hutch’s renowned program in blood stem cell transplantation. He also participated in Fred Hutch’s pioneering work to develop targeted antibody-based cancer therapies. Today, Dr. Appelbaum leads Fred Hutch’s Adult Leukemia Research Center and the Hematologic Malignancy Program of the Fred Hutchinson/University of Washington Cancer Consortium. These efforts are aimed at enhancing the understanding of these diseases and improving treatments like blood stem cell transplantation. In 2013, Dr. Appelbaum was elected as a member of the National Academy of Medicine. In 2019, he was one of 22 fellows elected to the American Association for Cancer Research Academy.

Margaret Bevans, Ph.D., R.N., FAAN,* is the director for the Office of Research Nursing at the National Heart, Lung, and Blood Institute (NHLBI) Office of the Clinical Director and is a captain in the U.S. Public Health Service. As the Director for the Office of Research Nursing, Dr. Bevans leads a team of research nurses and patient care coordinators who are committed to quality research and compassionate care through excellence in leadership, interdisciplinary collaboration, customer service, and clinical expertise. She provides organizational leadership for the NHLBI Office of the Clinical Director and advises on strategic initiatives and process improvement. Dr. Bevans is a well-established clinician, investigator, and leader in the field. Previously, Dr. Bevans was the Program Director and a Clinical Nurse Scientist in the

National Institutes of Health (NIH) Clinical Center studying the outcomes of cancer patients, specifically hematopoietic stem cell transplantation recipients and their caregivers. She is a member of the Oncology Nursing Society and the American Psychosocial Oncology Society and served as a cochair for the NIH Hematopoietic Stem Cell Transplant (HSCT) Late Effects Initiative Patient-Centered Outcomes Working Group. In addition, she served as an advisor for the National Marrow Donor Program (Be the Match) for a Patient and Caregiver Engagement Grant and Housing and Caregiver Needs study sponsored by The Patient-Centered Outcomes Research Institute. Her expertise includes patient-reported outcome methodology, including health-related quality of life and symptom assessment. She has served as principal and associate investigator for multiple NIH protocols and was inducted as a fellow into the American Academy of Nursing in 2014. Dr. Bevans received her bachelor’s degree from Johns Hopkins University and her master’s and doctorate degrees from the University of Maryland. She also holds assistant/adjunct faculty positions at the Uniformed Services University of the Health Sciences Graduate School of Nursing and the University of Maryland School of Nursing.

James Bowman, M.D., M.S., FACS, has been a senior physician with the Division of Transplantation Health Resources and Services Administration in the U.S. Department of Health and Human Services since 2009. Dr. Bowman supports the Division’s leadership in its oversight of the nation’s solid organ and blood stem cell transplant programs. Previously he served as senior medical officer with Chronic Care Policy Group at U.S. Centers for Medicare & Medicaid Services in support of Medicare payment policy for end-stage renal disease/dialysis units, inpatient rehab hospitals, skilled nursing facilities, home health agencies, hospital prospective payment systems, and the physician fee schedule. He has medical management experience with several national health insurers, and he served as a transplant and general surgeon in the U.S. Air Force and in civilian practice. Dr. Bowman is a fellow of the American College of Surgeons and participates with the American Society of Transplant Surgeons and the American Society for Blood and Marrow Transplantation. He earned his M.D. from Virginia Commonwealth University and his M.S. in management from NC State University. He trained in general surgery at Wright State University (Dayton, Ohio) and abdominal transplant surgery at the University of Pittsburgh and Children’s Hospital of Pittsburgh.

Cynthia E. Dunbar, M.D., is Chief, Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute (NHLBI), and Distinguished NIH Investigator at the National Institutes of Health in Bethesda, Maryland. Dr. Dunbar has pursued a career encompassing clinical investigation, basic science, and education. She graduated from Harvard College with an under-

graduate degree in the history of science followed by a medical degree from Harvard Medical School. Following internal medicine residency training at the Boston City Hospital, she joined NIH as a postdoctoral research fellow, training in the laboratory of Dr. Arthur Nienhuis. Following completion of clinical hematology training at the University of California, San Francisco, she returned to the NHLBI intramural program as a principal investigator in 1991. As a translational research scientist, she investigates hematopoiesis, stem cell biology, leukemogenesis, natural killer cell biology, and gene therapies targeting hematopoietic stem cells using nonhuman primate models predictive of human biology. She has carried out landmark clinical trials in gene therapies, transplantation, autoimmune disease, and bone marrow failure, including recent studies leading to the regulatory approval of the thrombopoietin mimetic eltrombopag as a new treatment for bone marrow failure. She was elected to the National Academy of Medicine in 2020. She is active in the leadership of major professional societies, including service as the past president of the American Society for Cell and Gene Therapy and as the current secretary of the American Society of Hematology. She served as editor-in-chief of the hematology journal Blood from 2007 to 2013, the first woman to serve in this position. She has led the NIH Assembly of Scientists, and made efforts throughout her career to foster gender and ethnic diversity in science and medicine and to support the career development of physician–scientists.

Mary M. Horowitz, M.D., M.S.,* is the Robert A. Uihlein Professor of Hematologic Research and Deputy Cancer Director at the Medical College of Wisconsin in Milwaukee. Dr. Horowitz has been involved in clinical research in hematopoietic stem cell transplantation (HSCT) for more than 35 years. She served as chief scientific director of the Center for International Blood and Marrow Transplant Research (CIBMTR) for 30 years and is now scientific director emeritus. The CIBMTR is a network of more than 350 centers worldwide that conduct clinical and translational studies focused on improving access to and outcomes of blood and marrow transplantation. Its more than 1,500 published studies include seminal articles defining optimal strategies for using unrelated donor and cord blood transplants, providing insight into the potent anticancer effects of transplantation and describing both malignant and non-malignant late effects. Dr. Horowitz is principal investigator for the Coordinating Center of the U.S. Blood and Marrow Clinical Trials Network, a multicenter group funded by the National Institutes of Health (NIH) to test new therapies to improve the safety and effectiveness of transplantation and cellular therapy. Dr. Horowitz has received numerous awards for her work to advance HSCT, including the American Society of Blood and Marrow Transplantation’s Lifetime Achievement Award in 2014, the 2019 American College of Physicians Harriet P. Dustan award

for outstanding science related to medicine, and the 2019 Aplastic Anemia and Myelodysplastic Syndrome Foundation’s Lifetime Achievement in Science Award. She is also dedicated to fostering the next generation of clinical scientists and received the American Society of Hematology’s Mentor Award for Clinical Science in 2010 for her work guiding, supporting, and promoting the training and career development of young investigators. She has served on numerous NIH advisory panels, coauthored more than 400 publications addressing diverse issues in HSCT bone marrow transplantation, and been continuously funded by the NIH since 1990.

Leslie S. Kean, M.D., Ph.D., is a physician–scientist with extensive laboratory and clinical expertise in transplantation, translational immunology, and cellular therapeutics. She is the Director of Pediatric Stem Cell Transplant at Boston Children’s Hospital and the Dana-Farber Cancer Institute, and she is the Stranahan Professor of Pediatrics at Harvard Medical School. She is the chair of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). Dr. Kean’s research program is focused on the immunology of hematopoietic stem cell transplantation, cellular therapeutics, and immune tolerance in allo- and autoimmune diseases. The overarching goal of her research is to understand the immune mechanisms underlying effective cellular therapeutics, with a specific focus on graft-versus-host disease (GVHD), transplant rejection, and the immune mechanisms of success and failure of CAR T cells. Dr. Kean’s work has led to the creation of multiple novel, major histocompatibility complex–defined nonhuman primate models of transplant, GVHD, and CAR T efficacy and toxicity, and to several first-in-disease clinical trials. She has used both the animal models and the mechanistic studies linked to her clinical trials to investigate the cellular and molecular mechanisms of immune reconstitution, GVHD, and CAR T-cell immunology, and to test the effect that novel immunomodulatory therapies can make on these processes.

David Scadden, M.D., is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He is professor and chair emeritus of the Harvard University Department of Stem Cell and Regenerative Biology. He cofounded and codirects the Harvard Stem Cell Institute with Prof. Douglas Melton. He is a hematologist/oncologist at the Massachusetts General Hospital where he founded and directs the Center for Regenerative Medicine and previously led the Hematologic Malignancies Program of the Massachusetts General Hospital Cancer Center. He is a member or fellow of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the American College of Physicians, and a former member of the Board of External Experts for the National Heart, Lung, and Blood Institute and the National Cancer Institute’s Board

of Scientific Counselors. He is an affiliate member of the Broad Institute of Harvard and MIT and a visiting scholar of Pembroke College, University of Cambridge, England. He cofounded the public companies, Fate Therapeutics and Magenta Therapeutics, and is a director of Agios Pharmaceuticals and Editas Medicines. His work emphasizes using multidisciplinary approaches to define novel therapies for blood diseases. He is credited with having first experimentally defined a mammalian stem cell niche and its role in malignancy. His work on blood stem cells has led to new approaches to bone marrow transplantation now in clinical trial. He received the E. Donnall Thomas Award from the American Society of Hematology for his “pioneering work on the bone marrow microenvironment.”

Alexis A. Thompson, M.D., M.P.H.,* is currently the hematology section head at Ann and Robert H. Lurie Children’s Hospital of Chicago in Chicago, Illinois. She holds the A. Watson and Sarah Armour Endowed Chair for Blood Diseases and Cancer at Lurie Children’s. She is also a professor of pediatrics at the Northwestern University Feinberg School of Medicine. Dr. Thompson is also the associate director for equity and minority health at the Robert H. Lurie Cancer Center and Northwestern University Feinberg School of Medicine. She has served on regional and national advisory committees for governmental agencies as well as nonprofit organizations focused on improving health care access, increasing workforce diversity, and reducing health disparities. Currently Dr. Thompson is president of the American Society of Hematology. She is an investigator on multicenter trials and as well as her own institutional clinical studies in thalassemia, sickle cell disease, and hemophilia. She has been a leader in multicenter collaborations, such as the National Heart, Lung, and Blood Institute–funded Thalassemia Clinical Research Network and the Sickle Cell Disease Implementation Consortium. Her clinical interests include hemoglobinopathies (thalassemia and sickle cell disease), bone marrow failure syndromes, and stem cell transplantation in pediatric patients.

WORKSHOP SPEAKERS AND MODERATORS

Staci D. Arnold, M.D., M.B.A., M.P.H., is associate professor of pediatrics at Emory University School of Medicine. She is also program director of General Hematology and director of the Comprehensive Bone Marrow Failure Clinic, Aflac Cancer & Blood Disorders Center, at Children’s Healthcare of Atlanta. She completed both her M.D. and pediatric residency at Duke University. She specialized in pediatric hematology after completing a fellowship and a Master of Public Health at Columbia University. She has particular expertise in the care of children undergoing treatments including stem cell transplantation for noncancerous disorders such as sickle cell anemia, aplastic anemia, and

bone marrow failure syndromes. In addition to caring for patients, Dr. Arnold conducts clinical research. She uses her training in business and medicine to conduct outcomes research to investigate patient-reported outcomes and the cost-benefit of novel and curative pediatric therapies.

Stella Davies, M.B.B.S., Ph.D., MRCP, is a professor of pediatrics, holder of the Jacob G. Schmidlapp endowed chair in pediatrics and director of the Division of Bone Marrow Transplantation at Cincinnati Children’s Hospital. Dr. Davies is the current president of the American Society of Transplantation and Cellular Therapy and is the principal investigator of two RO1 grants focused on complications of transplantation.

Steven Devine, M.D., is Chief Medical Officer at the National Marrow Donor Program (NMDP)/Be The Match and associate scientific director at the Center for International Blood and Marrow Transplant Research (CIBMTR). Prior to joining the NMDP, he was the director of the BMT Program at the Ohio State University Comprehensive Cancer Center. He served for 8 years as chair of the National Cancer Institute-funded Alliance Transplant Committee as well as a 2-year term as chair of the National Institutes of Health–funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Steering Committee. He is currently one of the three co-principal investigators for the BMT CTN Data Coordinating Center. He has a major research interest in the application of stem cell transplantation for patients with acute leukemia and myelodysplastic syndrome. He has authored more than 200 peer-reviewed papers and more than 400 abstracts as well as several reviews and book chapters in the field of stem cell transplantation, leukemia, and hematology. He is an associate editor for the ASTCT journal Transplantation and Cellular Therapy and a member of the Journal of Clinical Oncology editorial board.

Areej El-Jawahri, M.D., serves as the director of the Blood and Marrow Transplant Survivorship Program, the associate director of the Cancer Outcomes Research and Education Program, and the director of Digital Health at Massachusetts General Hospital. Dr. El-Jawahri is an oncologist specializing in the care of patients with hematologic malignancies and those undergoing hematopoietic stem cell transplantation and adoptive cellular therapy. Her goal is to improve the quality of life and care for patients with hematologic malignancies and their families. Her research interests include investigating patient-reported outcomes, developing interventions to enhance patient-centered decision making, and designing supportive, palliative, and digital health interventions to improve the care of patients with hematologic malignancies and their families. Dr. El-Jawahri graduated from Harvard Medical School and completed her residency training at Massachusetts General Hospital. She subsequently

completed her hematology–oncology fellowship at the Dana Farber Harvard Cancer Center Fellowship Program.

Betty K. Hamilton, M.D., is the interim director of the Blood and Marrow Transplant Program at the Cleveland Clinic Taussig Cancer Institute and associate professor of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Hamilton’s clinical and research interests focus on the treatment of hematologic malignancies with allogeneic hematopoietic cell transplantation, as well as improving outcomes posttransplant, specifically in graft-versus-host disease (GVHD), survivorship, and late effects. Her research interests are in novel ways to prevent and treat GVHD, and patient-centered outcomes in GVHD and associated late effects. Dr. Hamilton established and leads the Victor Fazio M.D. Cancer Survivorship Clinic for transplant recipients at the Taussig Cancer Institute. Dr. Hamilton is also currently the director for community/clinical practice of the American Society of Transplant and Cellular Therapy. She serves as cochair of the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research. She recently chaired the Late Effects, Quality of Life, and Economics Committee for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) State of the Science Symposium. Dr. Hamilton is an active investigator with the BMT CTN and site principal investigator on many GVHD prevention and therapeutic clinical trials, including active involvement in the National Institutes of Health (NIH) Chronic GVHD Consortium and participation in the 2020 NIH Chronic GVHD Consensus project.

Margaret Jurocko has been navigating the health care of her immune-comprised sons for more than 24 years while working in a variety of different industries ranging from pharmaceuticals and corporate production to managing her own private Pilates business. Her passion and determination to get a diagnosis for her sons led her to the National Institutes of Health where in 2015 both young men were diagnosed with XMEN. Unfortunately, people with XMEN have an increased risk of developing lymphoma driven by the Epstein-Barr virus (EBV). Both of her sons contracted EBV within days of one another and, as a result, her youngest needed a bone marrow transplant to reset and replenish his immune system in 2016. Her oldest has managed to maintain his disease on Intravenous Immune Globulin Therapy (IVIG). Five years later, Margaret continues to work faithfully to advocate and volunteer with Be The Match to support other caregivers, raise awareness of patient needs, and enrich her own life by giving others the love and respect that they need to live a purposeful life.

Stephanie J. Lee, M.D., M.P.H., is a member of the Fred Hutchinson Cancer Research Center and professor at the University of Washington. She holds the David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research. She is also the associate director of the Clinical Research Division and the research director of the Long-Term Follow-Up Program at Fred Hutchinson. Her research focuses on outcomes after hematopoietic cell transplantation, with a particular emphasis on chronic graft-versus-host disease. She is the past 2020 President of the American Society of Hematology.

Suzanne McCarroll is a Stanford alum and a long-time CBS News journalist. She loved her career choice. When she was diagnosed with lymphoma in 2011, she was able to juggle treatments and career. She went through RCHOP therapy and was in remission for 4.5 years. Since then she had two rounds of immunotherapy at the Fred Hutchinson Cancer Research Center in Seattle and two transplants (one at Dana Farber in Boston, the other in Denver). She has struggled with GVHD in her stomach and mouth. Ms. McCarroll is currently being treated at City of Hope in Los Angeles. Three years ago she had to quit her job, as television news reporting is not compatible with a compromised immune system. She often says that managing insurance claims and medicine is a full-time job.

Miguel-Angel Perales, M.D., is the chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, as well as an associate professor of medicine at Weill Cornell Medical College. He is an internationally recognized leader in the field of hematopoietic stem cell transplantation and cellular therapy and serves as chair of the Alliance for Clinical Trials in Oncology Transplantation and Cell-Based Therapies Committee, vice-chair of the Board of Directors of Be the Match (National Marrow Donor Program), and vice-president of the American Society for Transplantation and Cellular Therapy. He also holds leadership positions and has been extensively involved in activities of the Center for International Blood and Marrow Transplant Research and Blood and Marrow Transplantation Clinical Trials Network. Dr. Perales has more than 300 publications including peer-reviewed articles, position papers, guidelines, book chapters, editorials, and invited reviews, and has been an invited speaker at numerous national and international meetings over the past 20 years. Dr. Perales received his M.D. from the Free University of Brussels and completed postdoctoral training at the Tufts Medical Center and Memorial Sloan Kettering Cancer Center.

David L. Porter, M.D., is the Jodi Fisher-Horowitz Professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center,

and director of cell therapy and transplant at the University of Pennsylvania. He graduated from the University of Rochester and earned a medical degree at Brown University. He completed internship and residency at Boston University Hospital and fellowship training at Brigham and Women’s Hospital and Harvard Medical School. Dr. Porter chairs or serves on numerous local, national, and international committees focused on hematologic malignancies, stem cell transplantation, and cell therapy. He is the immediate past chair and current member of the Board of Directors of the National Marrow Donor Program and serves on a number of cell therapy advisory boards, monitoring boards, and steering committees for several organizations including the Foundation for the Accreditation of Cell Therapy, the Association of American Cancer Institutes, the Society for Immunotherapy of Cancer, and the Center for International Blood and Marrow Transplant Research. He is the recipient of several prestigious awards from local and national organizations that include recognition for service, professionalism, and mentorship. He has an extensive publication record and has been the primary or coauthor of more than 200 research and review articles. He currently serves as the deputy editor of Transplantation and Cell Therapy (formerly Biology of Blood and Marrow Transplantation), and he is an associate editor for the American Journal of Hematology. He has worked with colleagues at the University of Pennsylvania to pioneer successful development of CAR T cells. Other research highlights include development of novel methods to improve safety and outcomes after allogeneic stem cell transplantation.

J. Douglas Rizzo, M.D., M.S., is the associate director of Clinical Operations, senior scientific director at the Center of International Bone Marrow Transplant Research (CIBMTR), professor of medicine/hematology and oncology, and project director of the Stem Cell Therapeutic Outcomes Database. As the associate director of clinical operations for the Medical College of Wisconsin Cancer Center, he provides direction for cancer clinical operations while overseeing the multidisciplinary clinics and Cancer Service Line. Dr. Rizzo fosters a climate of multidisciplinary cancer care with a visible emphasis on research-driven patient care. He works closely with Froedtert administrative leadership and Medical College clinical leadership to ensure that MCW clinicians deliver top-quality cancer care and create an environment that is structured for and supports clinical research. He assists with implementation of community engagement strategies and integration of care across all Cancer Network locations. He is responsible for design and implementation of value-based care strategies—including CMS’ Oncology Care Model. Dr. Rizzo coordinates with counterparts at Children’s Hospital of Wisconsin to share knowledge and apply research-driven cancer care best practices. He is also the Project Director of the Stem Cell Therapeutic Outcomes Database, one component of the CW

Bill Young Cell Transplantation Program. As such he has responsibility for all aspects of collection and use of data to fulfill CIBMTR’s contractual obligations. Dr. Rizzo has more than 20 years’ experience collecting, managing, and analyzing HCT data, and he has been integrally involved in CIBMTR initiatives studying late effects and quality of life, regimen intensity and toxicity, and health economics and access disparities. He has participated in numerous quality-of-care initiatives within and beyond the HCT community. He has international recognition and plays an important part of CIBMTR’s collaborative international presence. Dr. Rizzo has been a key contributor to both screening and practice guideline efforts for HCT survivors from the CIBMTR.

Karen L. Syrjala, Ph.D., is a professor and director of biobehavioral sciences, and codirector of the Survivorship Program at the Fred Hutchinson Cancer Research Center. At the University of Washington School of Medicine, she is a professor in the Department of Psychiatry and Behavioral Sciences. She is a licensed clinical psychologist who established the Fred Hutch Psychiatry/Psychology Service and cofounded the Fred Hutch Survivorship Program. Among other national responsibilities, she has served on invited national panels to develop cancer-related guidelines, including for hematopoietic cell transplantation (HCT) and general cancer survivorship, pain, anxiety/depression, and other symptom management. Her research is focused on examining long-term outcomes and interventions to improve the lives of cancer survivors, with a focus on HCT. In prospective longitudinal studies, she has examined musculoskeletal, sexual, emotional, and physical function trajectories; neurocognitive recovery; health care adherence; and barriers to health care access in HCT survivors. Recent multicenter randomized controlled trials are looking at digital strategies for individualizing programs to meet HCT and other cancer survivor health needs, with a focus on cardiometabolic and subsequent malignancy health care adherence and management of emotional needs. She also leads mouse-to-human studies targeting the mechanisms for late complications in cancer survivors. Among journal editorial board invited memberships, she has been associate editor for the Journal of Cancer Survivorship. She mentors numerous junior faculty and fellows in cancer research across disciplines and provides clinical services to oncology patients.

John Tisdale, M.D., is chief of the Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). Dr. Tisdale received his medical degree from the Medical University of South Carolina in Charleston after obtaining his B.A. in chemistry from the College of Charleston. He completed an internal medicine and chief residency at Vanderbilt University Medical Center in Nashville and then trained in hematology in the Hematology Branch, NHLBI, where

he served as a postdoctoral fellow. He joined the Molecular and Clinical Hematology Branch of NHLBI in 1998. In 2020 the College of Charleston recognized Dr. Tisdale as one of its Top 25 History makers in honor of the school’s 250-year anniversary and was a Samuel J. Heyman Service to America Medal finalist. He was recently elected to the American Society for Clinical Investigation and is a member of the American Society of Hematology. He serves as an editorial board member of the journals Stem Cells, Experimental Hematology, and Molecular Therapy Methods & Clinical Development. He is a frequent ad hoc reviewer for Blood, New England Journal of Medicine, Human Gene Therapy, and Nature Medicine, Experimental Hematology, and Molecular Therapy to name a few. He has served on the National Institute of Diabetes and Digestive and Kidney Diseases/National Institute of Arthritis and Musculoskeletal and Skin Diseases Institutional Review Board for more than 15 years, is a founding member of the NIH Bone Marrow Transplant Consortium, and is an active member of the NIH Intramural Gene Therapy Task Force. Dr. Tisdale’s research and clinical work center on sickle cell disease. His group focuses on developing curative strategies for sickle cell disease through transplantation of allogeneic or genetically modified autologous bone marrow stem cells. He has published more than 200 first- and coauthor publications.